| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 0 | 0 | 0 | 5.747 | 2.076 | 12.111 | 39.284 |
| Total Income - EUR | - | - | - | 0 | 0 | 0 | 5.747 | 13.113 | 12.111 | 39.290 |
| Total Expenses - EUR | - | - | - | 402 | 1.099 | 3.013 | 6.160 | 13.996 | 7.624 | 11.114 |
| Gross Profit/Loss - EUR | - | - | - | -402 | -1.099 | -3.013 | -412 | -883 | 4.487 | 28.176 |
| Net Profit/Loss - EUR | - | - | - | -402 | -1.099 | -3.013 | -585 | -1.274 | 3.688 | 23.717 |
| Employees | - | - | - | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Naturapeutica Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 11.391 | 10.677 | 12.048 | 10.904 | 0 | 0 | 0 |
| Current Assets | - | - | - | 75 | 84 | 239 | 1.325 | 239 | 8.468 | 32.629 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 0 | 0 | 0 | 282 | 0 | 4.553 | 20 |
| Cash | - | - | - | 75 | 84 | 239 | 1.044 | 239 | 3.915 | 32.609 |
| Shareholders Funds | - | - | - | -359 | -1.409 | -4.395 | -4.883 | -6.171 | -2.465 | 21.266 |
| Social Capital | - | - | - | 43 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | - | - | - | 11.824 | 12.169 | 16.681 | 17.112 | 6.411 | 10.933 | 11.470 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Naturapeutica Med Srl